When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AKRO - Dosing underway in Akero's expanded cohort of Balanced trial in NASH
Akero Therapeutics Inc.
Akero Therapeutics (AKRO+1.6%) doses first subject in Cohort C, the expansion of its Phase 2a BALANCED trial, which will enroll 30 subjects who have non-alcoholic steatohepatitis (NASH) with compensated cirrhosis (F4), Child-Pugh Class A.
More news on: Akero Therapeutics, Inc., Healthcare stocks news,